Predicting Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
J. Natl. Cancer Inst 2020 Jun 09;[EPub Ahead of Print], M Bandini, JS Ross, D Raggi, A Gallina, M Colecchia, R Lucianò, P Giannatempo, E Farè, F Pederzoli, M Bianchi, R Colombo, G Gandaglia, N Fossati, L Marandino, U Capitanio, F Deho', SM Ali, R Madison, JH Chung, A Salonia, A Briganti, F Montorsi, A NecchiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.